Anticomplement therapies in “secondary thrombotic microangiopathies”: ready for prime time?

The term thrombotic microangiopathy (TMA) refers to a syndrome consisting of  microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction with normal coagulation parameters.1 The designations “primary” and “secondary” to TMA are arbitrary and reflect underlying mechanisms. The primary TMA syndromes include thrombotic thrombocytopenic purpura related t o a deficiency of the von Willebrand factor protease ADAMTS13, diarrhea-associated hemolytic uremic syndrome associated with infection with Shiga toxin producing enteric organisms, and complement-mediated TMA or atypical hemolytic uremic syndrome HUS (aHUS) resulting from inherited or acquired disor ders of the alternative pathway of complement.

Source: Kidney International - September 19, 2019 Category: Urology & Nephrology Authors: Jai Radhakrishnan Tags: Controversies in Nephrology Source Type: research